Hema Ramkumar

Hema Ramkumar

Company: Chief Executive Officer

Job title: Oculogenex


Preclinical Validation of an Epigenetic Modifier Gene Therapy for the Treatment of Dry AMD 1:15 am

Introduction of a therapy with a novel mechanism of action for dry AMD Efficacy data in multiple rodent models of dry AMD Presentation of a novel animal model of dry AMD with spaceflight to low earth orbitRead more

Panel Discussion – Reviewing the Current State of Dry AMD Preclinical Models & What the Future Looks Like? 12:45 pm

Brief overview of blue light, sodium iodate and mass cell degranulation models to set the context for this session Discussing the qualities of the ideal preclinical model to identify key areas of development Looking towards the next generation of animal models as for better recapitulation of human dry AMDRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.